NanoViricides develops broad-spectrum antiviral drug to combat severe flu season
ByAinvest
Tuesday, Jan 13, 2026 11:14 am ET1min read
NNVC--
NanoViricides is highlighting the need for broad-spectrum antivirals amid the current severe flu season, with over 15 million illnesses and 7,400 deaths reported. The company's drug candidate, NV-387, targets a host cell feature used by over 90% of human pathogenic viruses and has shown activity against Influenza A/H3N2, RSV, and coronaviruses in animal studies. NanoViricides plans a Phase II clinical trial to evaluate NV-387 as a potential first-line therapy for respiratory viral infections, with a potential market exceeding $20 billion.
Stay ahead of the market.
Get curated U.S. market news, insights and key dates delivered to your inbox.
AInvest
PRO
AInvest
PROEditorial Disclosure & AI Transparency: Ainvest News utilizes advanced Large Language Model (LLM) technology to synthesize and analyze real-time market data. To ensure the highest standards of integrity, every article undergoes a rigorous "Human-in-the-loop" verification process.
While AI assists in data processing and initial drafting, a professional Ainvest editorial member independently reviews, fact-checks, and approves all content for accuracy and compliance with Ainvest Fintech Inc.’s editorial standards. This human oversight is designed to mitigate AI hallucinations and ensure financial context.
Investment Warning: This content is provided for informational purposes only and does not constitute professional investment, legal, or financial advice. Markets involve inherent risks. Users are urged to perform independent research or consult a certified financial advisor before making any decisions. Ainvest Fintech Inc. disclaims all liability for actions taken based on this information. Found an error?Report an Issue
Comments
No comments yet